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Abstract
Currently over 30 000 allogeneic hematopoietic stem cell (HSC) transplantations
have been performed for the treatment of hematological and nonhematological dis-
eases using HSC from umbilical cord blood (CB). However, the wide utilization of CB
as a source of HSC is limited by the low number of cells recovered. One strategy to
expand ex vivo CB-HSC is represented by the use of bone marrow mesenchymal
stromal cells (BM-MSCs) as a feeder to enhance HSC proliferation while maintaining
HSC stemness. Indeed, BM-MSCs have been recognized as one of the most relevant
players in the HSC niche. Thus, it has been hypothesized that they can support the
ex vivo expansion of HSC by mimicking the physiological microenvironment present in
the hematopoietic niche. Due to the role of placenta in supporting fetal hematopoiesis,
MSC derived from the amniotic membrane (hAMSC) of human term placenta could
represent an interesting alternative to BM-MSC as a feeder layer to enhance the prolif-
eration and maintain HSC stemness. Therefore, in this study we investigated if hAMSC
could support the ex vivo expansion of HSC and progenitor cells. The capacity of
hAMSCs to support the ex vivo expansion of CB-HSC was evaluated in comparison to
the control condition represented by the CB-CD34+ cells without a feeder layer. The
coculture was performed at two different CD34+:MSC ratios (1:2 and 1:8) in both cell-
to-cell contact and transwell setting. After 7 days, the cells were collected and analyzed
for phenotype and functionality. Our results suggest that hAMSCs represent a valuable
alternative to BM-MSC to support: (a) the ex vivo expansion of CB-HSC in both con-
tact and transwell systems, (b) the colony forming unit ability, and (c) long-term culture
initiating cells ability. Overall, these findings may contribute to address the unmet need
of high HSC content in CB units available for transplantation.
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Significance statement
To date, more than 30 000 allogeneic hematopoietic stem cell (HSC) transplantations for the
treatment of hematological and nonhematological diseases have been performed using HSC
from umbilical cord blood (CB). However, the wide utilization of CB as a source of HSC is limited
by the low number of cells recovered and thus they need to be expanded. This article shows
that placenta-derived cells represent a valuable option and can support the ex vivo expansion of
HSC and hematopoietic progenitor cells. Placenta-derived cells could contribute to address the
unmet need of high HSC content in CB units available for transplantation.
1 | INTRODUCTION
During the last 20 years, umbilical cord blood (CB) has become an
attractive source for allogeneic hematopoietic stem cell (HSC) trans-
plantation in addition to other sources such as bone marrow
(BM) aspirates.1-4 Indeed, CB is easily available with a low risk of graft
vs host disease and a high presence of HSCs and hematopoietic pro-
genitor cells (HPCs). However, the limited number of HSC and HPC
obtained from a single CB unit remains insufficient for the complete
reconstitution of BM hematopoiesis in an adult patient.1,5 Many
efforts have been made to circumvent this limitation by a double cord
transplant,6 or by the ex vivo expansion of the HSC and HPC.7,8 As a
matter of fact, a cocktail of selected cytokines relevant for their role
on hematopoiesis and engraftment is nowadays used for the ex vivo
expansion. Three of these, stem cell factor (SCF), thrombopoietin
(TPO), and the Feline McDonough sarcoma (FMS)-like tyrosine kinase
3 ligand (Flt3-L), have been reported as important for triggering the
proliferation, stemness maintenance, and improved engraftment of
the ex vivo-expanded CB-HSC.9,10 In addition, copper chelating
agents11,12 or transcriptional activators and inhibitors13-15 have also
been used to increase HSC and HPC numbers for transplantation.
Currently, the use of feeder cells in combination with various
cytokine cocktails to mimic the niche microenvironment is being
investigated.1,7,8,16 Importantly, in the HSC niche, mesenchymal stro-
mal cells (MSCs) play a pivotal role by regulating the complex molecu-
lar signaling involved in HSC homeostasis.17-20 Nowadays, BM-
derived MSC (BM-MSC) represent the elective source of MSC consid-
ering their function in the HSC niche. However, over the years, sev-
eral groups reported that MSC derived from perinatal tissues, such as
amniotic membrane,21 chorionic villi,22-24 maternal decidua
basalis,25,26 and from the umbilical cord (including Wharton's
jelly),27,28 can constitute an alternative feeder to BM-MSC.
During fetal development, the placenta partly supports hemato-
poiesis, and thus it is conceivable that it is endowed with characteris-
tics common to the hematopoietic niche.29-31 Moreover, perinatal
tissues are considered biological waste after term delivery and are
therefore widely available.
Of particular interest are MSC derived from the amniotic mem-
brane of term placenta (hAMSC). They present a phenotype consis-
tent with MSC from fetal membranes, as suggested by a consensus
paper established during the First International Workshop on
Placenta-Derived Stem Cells in 2008.21,32 In fact, these cells are
marked by the classical MSC proteins CD90, CD44, CD73, and
CD105, while they lack hematopoietic markers CD45, CD34, CD14,33
and human leukocyte antigen-antigen D-related (HLA-DR) and pre-
sent the in vitro differentiation potential toward one or more lineages
including osteogenic, adipogenic, chondrogenic, and vascular/endo-
thelial.21,34 hAMSC also have immunomodulatory activity and are pro-
posed as treatments of inflammatory-related disorders.35,36 Indeed,
several papers reported that hAMSC transplantation triggers regener-
ation in animal models of liver37 and lung fibrosis,38 collagen-induced
arthritis, inflammatory bowel disease, dextran-induced severe colitis,
experimental autoimmune encephalomyelitis (EAE, an animal model
for multiple sclerosis),39 traumatic brain injury,40 and cardiac ische-
mia.41 The therapeutic effects were observed in the absence of cell
engraftment in the injured tissue suggesting that hAMSC act in a para-
crine manner.35,36 This hypothesis was confirmed by studies using
conditioned medium (CM) derived from hAMSC that also demon-
strated beneficial effects in preclinical models of lung fibrosis,42,43 car-
diac ischemia,44 Huntington's disease,45 and skin wound in diabetic
mice.46
Herein, we investigated if hAMSC could represent a valid alterna-
tive to BM-MSC as a feeder layer to support HSC and HPC ex vivo
expansion. We assessed the expansion and maintenance of the most
primitive long-term HSC (LT-HSC), as well as the expansion of short-
term HSC (ST-HSC) that are known to rapidly reconstitute the HSC
niche. We also investigated the expression of adhesion molecules
involved in stemness maintenance and homeostasis of HSC. Our find-
ings suggest that hAMSC can be a valid alternative to BM-MSC for
the ex vivo expansion of the CB-HSC that could help meet the grow-
ing needs of HSC for transplants.
2 | MATERIALS AND METHODS
2.1 | Ethics statements
Amniotic membrane-derived MSC (hAMSC) (n = 11) isolated from
human term placenta and CB mononuclear cells (CB-MNC) (n = 12)
were obtained from healthy women after full-term vaginal delivery or
caesarean section.
BM-MSC (n = 9) were obtained from BM aspirates from healthy
donors.
Samples were processed after informed written consent.
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2.2 | MSC isolation from human BM
BM-MSCs were isolated by plastic adherence as previously
described.47 After isolation, MNCs were then seeded at a density of
0.5  106 cells/cm2 in low glucose Dulbecco's modified Eagle's
medium (DMEM), supplemented with 10% fetal bovine serum (FBS),
1% L-glutamine (200 mM L-Glu), and 1% penicillin and streptomycin
(P/S, 10.000 U P and 10 mg/ml; all from Merck, St. Louis, Missouri).
Every 3 days, nonadherent cells were removed, and fresh
complete medium was added. Cells were expanded until 80% con-
fluency and then detached with Trypsin/EDTA solution (0.25%,
Merck) and expanded until passage 2 (p2) by plating at a density of
1  104 cells/cm2 in DMEM complete medium at 37C in 5% CO2.
The cells were cryopreserved in liquid nitrogen at the final con-
centration of 1  106 cells/mL in FBS supplemented with 10%
dimethyl sulfoxide (DMSO) (Merck) until use.
2.3 | MSC isolation from human amniotic
membrane
MSCs derived from the human amniotic membrane (hAMSC) were
isolated from human term placentas of healthy women. Isolation, phe-
notype characterization, and cryopreservation were carried out as
previously described.48
Amnion fragments were digested at 37C for 9 minutes with 2.5
U/mL dispase (VWR, Radnor, Pennsylvania); samples were then trans-
ferred to RPMI complete medium composed of RPMI 1640 medium
supplemented with 10% heat-inactivated FBS, 1% P/S, and 1% L-glu-
tamine. Enzymatic digestion continued with the treatment of the
amnion fragments with 0.94 mg/mL collagenase and DNase I (both
from Roche, Basel, Switzerland) for approximately 2.5 to 3 hours at
37C. The resulting cell suspensions were centrifuged at 150g. The
supernatant was filtered through a 100-μm cell strainer (from BD Fal-
con, Bedford, Massachusetts) and the cells were collected by centrifu-
gation. Freshly isolated (p0) cells were then cryopreserved in liquid
nitrogen at the final concentration of 1  106 cells/mL in FBS sup-
plemented with 10% DMSO until their use.
2.4 | Analysis of BM-MSC and hAMSC phenotype
Both BM-MSC and hAMSC cell populations were analyzed by flow
cytometry for the expression of canonical MSC markers21,33,49: CD90
(clone 5E10), CD105 (clone 266), CD73 (clone AD2), the absence of
hematopoietic markers such as CD45 (clone HI30) and CD34 (clone
581/CD34), and of epithelial markers as CD324 (clone 67A4), the
expression of histocompatibility markers as HLA-ABC (clone
G46-2.6), HLA-DR (clone TU36), and the expression of markers
involved in the maintenance of HSC stemness: nestin (clone
25/NESTIN), ICAM-1/CD54 (clone HA58), and PDGFR-β/CD140b
(clone 28D4).18,50 All antibodies were purchased from BD Biosciences
(BD Biosciences, Franklin Lakes, New Jersey). Cells were kept in
culture for 24 hours in StemSpan™ SFEM (Stemcell Technologies,
Vancouver, Canada) medium in order to mimic the experimental
coculture condition. Then, cells were harvested, counted, and trans-
ferred in micronic tubes (Micronic B.V., the Netherlands). Cells were
washed with PBS and centrifuged at 450g for 5 minutes at 4C. The
supernatants were discarded, and cells were stained with 40 μL of
eBioscienceTM Fixable Viability Dye eFluorTM 780 (Thermo Fisher Sci-
entific, Massachusetts) (diluted 1:1600 in PBS) for the exclusion of
dead cells according to the manufacturer instructions. Blocking was
performed with immunoglobulin solution (30 μL/sample).
Cells were then stained for all the aforementioned markers at 4C
for 30 minutes. Intracellular staining for nestin was performed at
4C for 30 minutes upon fixation and permeabilization was performed
with BD Cytofix/Cytoperm buffer (BD Biosciences). Antigen expres-
sion was detected using FACSAria III (BD Biosciences) and data were
analyzed with FCS express v5 software (De Novo Software, Los
Angeles, California).
2.5 | Mononuclear and CD34+ cell isolation from
human umbilical CB
Samples were collected by umbilical CB aspiration using CB collection
set (JMS Singapore Pte Ltd) and processed immediately. CB-MNCs
were isolated over a Ficoll-paque density gradient medium (1.077
g/mL) (Merck) and centrifuged at 800g for 30 minutes. CB-MNC were
then cryopreserved in liquid nitrogen at the final concentration of
20  106 cells/mL in FBS supplemented with 10% DMSO until
their use.
CD34+ HSCs were purified from total CB-MNC by positive selec-
tion using anti-CD34-coated microbeads and MACS® separation col-
umns following manufacturer instructions (Miltenyi Biotec, Bergisch
Gladbach, Germany).
To increase the purity of CD34+ cells, the eluted positive frac-
tions were enriched by a second magnetic separation in Medium Size
column (MS, Miltenyi Biotec). Finally, the CD34+ cell number and via-
bility were determined by Trypan blue exclusion assay. The obtained
samples of CD34+ cells showed a purity > 95% evaluated by flow
cytometry using FACSAria III. Data were analyzed with FCS express
v5 software (De Novo Software).
2.6 | CB-CD34+ cells and MSC cocultures
To analyze the effect of the two different MSC feeders on CD34-HSC
ex vivo expansion, BM-MSC and hAMSC were seeded in 24 well
plates (Corning, New York, USA) in StemSpan™SFEM (Stemcell Tech-
nologies, Vancouver, Canada) medium at two different concentra-
tions, 40,000 and 160,000 cells in 0.5 ml per well, and allowed to
adhere overnight. The day after, MSC were gamma-irradiated at 30Gy
to block cell proliferation and CD34+ isolated HSC (20,000 cells/ in
0.5 ml) were added. The coculture was thus performed with two dif-
ferent CD34+-MSC ratios (1:2 and 1:8). Stem Span SFEM culture
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medium was supplemented with three cytokines necessary for the
expansion and overall survival of CD34+ cells51,52: SCF, Flt-3L and
TPO at the concentration of 30 ng/ml each (all from Miltenyi Biotec).
Cocultures were established either in cell-to-cell contact or using
transwell chambers (0.4 μm pore, polycarbonate membrane; Corning).
To detect the basal effect of the cytokine cocktail on the ex vivo
expansion of CD34+ cells, the control condition represented by the
ex vivo expansion in absence of a feeder layer was included.
Cocultures and CD34+ cells cultured alone were incubated for
7 days at 37C in humidified atmosphere and 5% CO2. After 7 days,
the mixed population composed of CD34+ HSC and MSC, as well as
the CD34+ HSC cultured alone representative of the basal condition,
was collected and cell proliferation and viability were determined by
Trypan blue exclusion assay. Cells were then analyzed for their
phenotype.
2.7 | Flow cytometry analysis of ex vivo-expanded
CB-CD34+ cells
The ex vivo-expanded CD34+ cells as well as time zero (T0) freshly
isolated CD34+ cells seeded to perform the coculture were phenotyp-
ically analyzed for a panel of antibodies to identify and discriminate
primitive CD34+ cells from the most advanced progenitor.
Cells were harvested as described in paragraph 2.4 and stained with
anti-CD45 (clone HI30), anti-CD45RA (clone REA562), anti-CD34
(clone581) and anti-CD38 (clone LS198-4-3), anti-CD133 (clone AC133),
and anti-CD7 (clone M-T701) for lymphoid progenitors, anti-CD33 (clone
P67.6) for myeloid progenitors, and CD71 (M-A712) for megakaryocyte-
erythrocyte progenitors. In detail, LT-HSCs were identified as CD45RA-
CD34+CD38CD133+, ST-HSCs as CD45RACD34+CD38+CD133.
For analysis of HPC and most committed progenitors, the gating strategy
was the following: HSC/multipotent progenitors (MPPs) were identified
as CD34+CD38CD45RACD133+CD7; lymphoid-primed multipotent
progenitors (LMPP) as CD34+CD38CD45RA+CD133CD7, multi lym-
phoid progenitors (MLP) as CD34+CD38CD45RA+CD133CD7+; com-
mon myeloid progenitors (CMP) as CD34+CD38+CD45RAC
D7CD71; the granulocyte-monocyte progenitors (GMP) as
CD34+CD38+CD45RA+CD7CD33+ and, finally, megakaryocyte-eryth-
rocyte progenitors (MEP) as CD34+CD38+CD45RCD7CD71+.53,54 All
antibodies were purchased from BD Biosciences except for CD34 that
was purchased from Becton Dickinson. Cells were acquired using
FACSAria III and the analyzed with FCS express v5 software (De Novo
Software).
2.8 | Colony forming unit (CFU) assay
The clonogenic capacity of CD34+ cells expanded after 7 days of
coculture with BM-MSC, hAMSC, or in the control condition was
evaluated by short-term CFU assay. Cells for burst-forming units ery-
throid (BFU-E), colony-forming unite granulocyte-macrophage (CFU-
GM), and CFU-granulocyte/macrophage/erythroid/megakariocyte
(CFU-GEMM) were seeded in duplicate in methylcellulose MethoCult
H4434 classic medium (Stemcell Technologies) in 35 mm petri dishes
(Corning). Cells were incubated for fourteen days at 37C in a humidi-
fied atmosphere at 5% CO2 according to the manufacturer's instruc-
tions. After 14 days, BFU-E, CFU-GM, and multilineage colonies
(GEMM) were scored in situ.
2.9 | Long-term culture-initiating cell (LTC-IC): bulk
culture assay
To evaluate the capacity of ex vivo CD34+ cells expanded in the pres-
ence of the two different MSC feeders, as well as in the control condi-
tion, to support long-term hematopoietic cell niche reconstitution,
CD34+ cells harvested from primary cocultures with BM-MSC or
hAMSC were tested for LTC-IC assay. M2-10B4 cells (Stemcell Tech-
nologies) were thawed, irradiated (80 Gy), and 3  105 cells were
seeded on collagen-coated (Merck) six-well plates (Corning) in Myelo-
Cult H5100 medium (Stemcell Technologies) supplemented with 106
M hydrocortisone (Stemcell Technologies) and allowed to adhere
overnight. The day after, 30 000 CD34+ expanded cells were added
to each well. Cultures were maintained for 6 weeks at 37C in 5%
CO2,
55-57 with half-medium changes once per week. After 6 weeks,
the total cell fraction composed by a mix of nonadherent and
trypsinized adherent cells of each culture was harvested, counted with
Trypan blue exclusion dye, and 50 000 cells were seeded in Met-
hoCult H4435 Enriched medium (Stemcell Technologies) 35 mm dis-
hes for the CFU assay and the total number of colonies obtained were
counted after 14 days.
The frequency of LTC-IC in the starting cell population and the
average number of CFU derived from each LTC-IC were calculated as
previously reported.58-60
2.10 | Statistical analysis
The data are displayed as truncated violin plots histograms with
median and quartile. The parameters were compared using one- or
two-way analysis of variance. Data are representative of at least four
independent experiments. Statistical analysis was performed using
Prism 8 (GraphPad Software, La Jolla, California). A P-value lower
than .05 was considered statistically significant.
3 | RESULTS
3.1 | hAMSCs and BM-MSCs present similar
immunophenotype
BM-MSCs and hAMSCs were confirmed to be morphologically similar
(Figure 1A). Both MSC cell populations expressed the canonical MSC
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F IGURE 1 A, Bright-field microscopy was used to analyze mesenchymal stromal cell (MSC) morphology; scale bar = 500 μm. B,
Immunophenotype of human bone marrow MSCs (BM-MSCs) and amniotic mesenchymal stromal cells (hAMSCs). Phenotype was analyzed by
flow cytometry and in (C) the percentage of positive BM-MSCs (triangle) or hAMSCs (circle) for each marker was represented. Data are presented
as mean ± SD (**P ≤ .01, ****P ≤ .0001) and they are representative of ≥5 different MSC donors. APC, allophycocyanin; BV-421, brilliant violet
421; FITC, fluorescein isothiocyanate; PE, phycoerythrin
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markers CD90, CD105, and CD7321,33 and had a low/absent expres-
sion of hematopoietic markers (CD45 and CD34) and of the epithelial
marker CD324 (Figure 1B,C). Moreover, both BM-MSCs and hAMSCs
expressed HLA-ABC, and were negative for HLA-DR. In addition, both
BM-MSC and hAMSC also expressed markers essential for HSC
stemness: CD54/ICAM-1 (62.61% ± 16.83 SD vs 63.4% ± 0.3 SD);
nestin (83.15 ± 22.84 SD vs 63.01% ± 12.76 SD); and CD140b
(96.89% ± 3.65 SD vs 48.48% ± 8.04 SD), with a significant difference
observed for the expression of CD140b.
3.2 | hAMSCs support the ex vivo expansion of
CB-HSC not only in contact-dependent culture but
also in transwell system
The capacity of hAMSCs to support the ex vivo expansion of CB-HSC
cells was evaluated in comparison to the control condition represen-
ted by the CB-CD34+ cells without feeder layer. The coculture was
performed at two different CD34+:MSC ratios (1:2 and 1:8) in both
cell-to-cell contact and transwell conditions. Data were analyzed as
total number of cells counted (Figure 2A) and as fold increase
(Figure 2B) obtained by the ratio between the total number of cells
collected after 7 days of coculture with MSCs vs the basal control
condition (CTR) (first lane Figure 2A).
In cell-to-cell contact, both concentrations of BM-MSCs induced
a significant increase of the ex vivo-expanded HSCs with a fold
change of 2.39 ± 0.73 SD and 2.41 ± 1.01 SD, respectively, in com-
parison to the CTR (Figure 2B). Similar results were obtained for the
transwell setting where there was a 2.55 ± 1.26 SD and 3.09 ± 1.31
SD fold increase compared with the CTR (Figure 2B). Notably, in cell-
to-cell contact, hAMSCs were able to induce a stronger proliferation
reaching a fold increase of 3.27 ± 0.99 SD and 4.23 ± 1.53 SD (1:2
and 1:8, respectively). Both ratios of hAMSCs in the transwell setting
supported ex vivo expansion of CD34+ cells with a fold increase of
2.98 ± 1.39 SD and 5.63 ± 2.09 SD (1:2 and 1:8, respectively)
(Figure 2B).
3.3 | hAMSCs expand both short-term and long-
term HSC
Different studies have correlated the proliferation rate with the differen-
tiation state of CD34+ cells.61-63 In order to evaluate the ability of the
two MSC feeders not only to favor CD34+ ex vivo expansion, but also
to preserve their stemness, the expansion of the primitive progenitor
subpopulations, named LT-HSC (identified as CD34+CD38CD133+)
and ST-HSC (identified as CD34+CD38+CD133), was evaluated by
immunophenotype analysis (Figure 3).
At both CD34+:MSC ratios analyzed, BM-MSCs induce a modest
expansion of LT-HSC in the contact setting (2.63 ± 0.71 SD and 2.46
± 1.03 SD for 1:2 and 1:8, respectively) compared with the CTR con-
dition represented by CD34+HSC cultured alone. Comparable results
were obtained for BM-MSCs in the transwell setting (2.76 ± 1.88 SD
and 2.55 ± 2.15 SD for 1:2 and 1:8 ratios, respectively). Similar find-
ings were observed with hAMSCs that were able, in cell-to-cell con-
tact, to stimulate the ex vivo expansion of LT-HSC (1:2 CD34+:MSC
ratio 3.19 ± 3.22 SD vs the CTR condition).
On the other hand, the 1:8 CD34+:MSC ratio determined only a
slight increase (0.75 ± 0.38 SD vs the CTR condition). At both ratios in
the transwell setting, only a slight increase in the total amount of LT-
HSC was observed in comparison to the CTR (2.73 ± 2.24 SD and
2.84 ± 3.29 SD fold change vs CTR for CD34+:hAMSC 1:2 and 1:8,
respectively) and comparable to what previously observed for the
BM-MSCs at the same culture condition.
Furthermore, a higher increase of ST-HSC in the presence of
BM-MSCs was observed in the contact setting (4.22 ± 1.60 SD and
7.17 ± 2.81 SD for 1:2 and 1:8, respectively), while in the transwell
setting a significant increase was observed with the highest BM-
MSC concentration (5.69 ± 2.64 SD and 12.79 ± 6.57 SD for 1:2 and
1:8, respectively). In addition, at the highest hAMSC concentration,
there was an increase of ST-HSC, stronger than that observed when
BM-MSCs were used at the same CD34+:MSC ratio (33.70 ± 10.94
for the hAMSCs vs 7.17 ± 2.81 SD for BM-MSCs). These findings
were confirmed also for the transwell setting (8.61 ± 5.91 SD and
43.40 ± 15.65 fold increase hAMSCs vs CTR for the 1:2 and 1:8
ratios).
F IGURE 2 Effects of human amniotic mesenchymal stromal cells
(hAMSCs) and bone marrow mesenchymal stromal cells (BM-MSCs)
on cord blood hematopoietic stem cells (CB-HSC) ex vivo expansion.
The cocultures were performed with HSCs and BM-MSCs or hAMSCs
at two different CD34+:MSC ratios (1:2 and 1:8), either in cell-to-cell
contact (full) or transwell (oblique lines) setting for 7 days in serum-
free medium supplemented with a cytokine cocktail composed by
stem cell factor (SCF), FMS-like tyrosine kinase 3 ligand (Flt3-L), and
thrombopoietin (TPO). The control condition, indicated as CTR, is
representative of the ex vivo expansion in the absence of a feeder
layer. Results are expressed as total number of cells collected after
7 days of ex vivo expansion. Data are represented as mean ± SD
(*P ≤ .05, **P ≤ .01) from ≥ 4 independent experiments
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3.4 | hAMSCs support the expansion of both
primitive and committed HPC subsets
The ability of the different feeder layers to foster the expansion of
primitive HSC and the different HPC subpopulations was analyzed.
Herein, the effect of BM-MSCs and hAMSCs on the commitment
toward different primitive HPC lineages (HSC/MPP, LMPP, MLP), as
well as on the most committed lineages (CMP, MEP and GMP), was
analyzed (Figure 4).
No significant differences were observed among the different cul-
ture conditions in the most primitive population represented by
HSC/MPP (Figure 4A). Indeed, in contact and transwell, both ratios of
BM-MSCs were able to trigger an increase in the amount
of HSC/MPP cells (for contact: fold increase of 3.4 ± 2.4 SD and 7.42
± 6.19 SD 1:2 and 1:8 ratios, respectively; for transwell: 3.91 ± 2.43
SD and 5.39 ± 3.70 SD 1:2 and 1:8 ratios, respectively).
Interestingly, hAMSCs in the contact setting and at a 1:2 ratio
with CD34+ led to a strong increase in the number of HSC/MPP cells
(11.68 ± 12.16 SD fold change vs CTR). The other three hAMSCs cul-
ture conditions: the 1:8 ratio in contact and both the transwell set-
tings (1:2 and 1:8 ratios) lead to an increase in the primitive
subpopulations with findings comparable to what observed for the
BM-MSC feeder layers, at the same ratio and culture conditions (2.48
± 1.29 SD, 4.30 ± 2.92 SD, and 6.67 ± 5.63 SD, respectively).
On the other hand, a significant increase in the LMPP subpopula-
tion was observed in the presence of both BM-MSCs and hAMSCs, in
either contact or transwell setting and at both ratios (1:2 and 1:8),
compared with the CTR. At the 1:2 ratio, the effects of hAMSCs and
BM-MSC were comparable (2.55 ± 0.52 SD for BM-MSCs vs 2.45
± 0.34 SD for hAMSCs). At the 1:8 ratio, hAMSCs resulted in a
reduced capability to trigger the expansion of LMPP in comparison to
what observed for the BM-MSCs (2.02 ± 0.43 SD for BM-MSCs
vs0.71 ± 0.29 SD for hAMSCs), while for the transwell setting the
amount of ex vivo-expanded LMPP was comparable to what was pre-
viously observed for BM-MSCs (2.66 ± 1.75 SD and 2.33 ± 2.12 SD
for 1:2 and 1:8 ratios, respectively for BM-MSCs vs 2.92 ± 2.25
SD and 2.8 ± 3.22 SD for the 1:2 and 1:8 ratios, respectively for
hAMSCs).
No significant differences were observed in MLP compartment
among the different conditions.
Importantly, concerning the effects of MSCs on the less primitive
compartments (Figure 4B), hAMSCs were able to significantly induce
the ex vivo expansion of committed HPC toward the CMP or GMP
compartments and, to a lesser extent, the MEP compartment. In partic-
ular, a fold increase of 4.53 ± 1.55 SD and 7.54 ± 2.15 SD for both
CD34+:MSC ratios in the contact setting was observed in the CMP
compartment, and similar findings were observed in the transwell set-
ting (5.77 ± 2.76 SD and 13.11 ± 8.54 SD for 1:2 and 1:8 BM-MSCs
ratios, respectively, in comparison to the CTR). hAMSCs at both ratios
were able to lead to a strong increase of 12.01 ± 5.63 SD and 22.03
± 12.50 SD for 1.2 and 1:8 ratios, respectively, vs the CTR for the con-
tact setting. This was also confirmed for the transwell setting where a
stronger increase was observed for the higher CD34+: MSC ratio
(11.30 ± 7.22 and 34.25 ± 17.92, respectively, for 1:2 and 1:8 ratios).
Moreover, BM-MSCs and most of all hAMSCs were able to
increase the MEP compartment, at both ratios and in both contact
and transwell settings (6.05 ± 1.41 SD and 11.83 ± 3.31 SD for BM-
MSCs vs 16.09 ± 6.24 and 21.90 ± 6.72 SD for hAMSC in contact set-
ting). The transwell setting triggered a stronger increase for both
feeder layers and once again the highest increase was obtained when
F IGURE 3 Effects of human amniotic mesenchymal stromal cells (hAMSCs) and bone marrow mesenchymal stromal cells (BM-MSCs) on
hematopoietic stem cell (HSC) subpopulations: long-term (LT-HSC) and short-term (ST-HSC). The cocultures were performed with CD34+ cells
and BM-MSCs or hAMSCs at two different CD34+:MSC ratios (1:2 and 1:8), either in cell-to-cell contact (full) or transwell (oblique lines) settings,
for 7 days in serum-free medium supplemented with a cytokine cocktail (stem cell factor [SCF], FMS-like tyrosine kinase 3 ligand [Flt3-L], and
thrombopoietin [TPO]). The control condition, indicated as CTR, represents the ex vivo expansion in the absence of a feeder layer. Results are
expressed as total number of LT-HSC (CD34+CD38CD133+) and ST-HSC (CD34+CD38+CD133) normalized to the total amount of CD34+
cells after 7 days coculture. Data are represented as mean ± SD (*P ≤ .05, **P ≤ .01, ***P ≤ .001, and ****P ≤ .0001) from ≥ 4 independent
experiments
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the coculture was performed with hAMSCs (12.53 ± 13.58 SD and
17.90 ± 19.67 SD for BM-MSCs vs7.69 ± 2.54 SD and 32.94 ± 21.53
SD for hAMSCs).
Finally, in the GMP compartment, both MSC, but once again most
of all hAMSCs, were able to strongly induce the expansion and polari-
zation toward this progenitor subset. Indeed, for both settings and
especially at the highest CD34+:MSC ratio, hAMSCs significantly
induced the ex vivo expansion of GMP cells in comparison to the
CD34+ cells expanded using the BM-MSCs feeder layer (13.05 ± 1.4
SD and 13.97 ± 9.47 SD for 1:2 ratio with hAMSCs in contact and
transwell settings, respectively, vs 5.14 ± 1.39 SD and 5.96 ± 4.01 SD
for BM-MSC in contact and transwell settings, respectively). These
differences were significant at the 1:8 ratio and for both settings
(12.17 ± 9.86 SD and 13.70 ± 9.45 SD for BM-MSCS vs 47.84
± 23.69 SD and 57.61 ± 19.25 for hAMSCs).
These findings confirm those in Figure 3, where hAMSCs induced
a stronger increase in the ST-HSC subset in comparison to the most
primitive LT-HSC.
3.5 | hAMSCs support the clonogenic ability of CB
progenitor cells
A CFU assay was performed in order to evaluate the hematopoietic
clonogenic ability of the ex vivo-expanded CB-HPC in different cul-
ture conditions.
F IGURE 4 Effects of human amniotic mesenchymal stromal cells (hAMSCs) and bone marrow mesenchymal stromal cells (BM-MSCs) on HSC
and hematopoietic progenitor cell (HPC) subpopulations. The cocultures were performed with CD34+ cells and BM-MSCs or hAMSCs at two
different CD34+:MSC ratios (1:2 and 1:8, either in cell-to-cell contact (full) or in transwell (oblique lines) setting for 7 days in serum-free medium
supplemented with a cytokine cocktail (stem cell factor [SCF], FMS-like tyrosine kinase 3 ligand [Flt3-L], and thrombopoietin [TPO]). The control
condition, indicated as CTR, is representative of the ex vivo expansion in the absence of a feeder layer. MSC were analyzed for their effects on
the commitment toward (A) different primitive HPC lineages (HSC/MPP, LMPP, MLP) and (B) on committed lineages (CMP, MEP, and GMP). The
results are described as fold increase obtained by the ratio between the total number of cells collected after 7 days of coculture with MSCs vs the
control condition (CTR). Data are represented as mean ± SD (*P ≤ .05, **P ≤ .01, ***P ≤ .001, and ****P ≤ .0001) from ≥ 4 independent
experiments. CMP, common myeloid progenitor; GMP, granulocytic monocytic progenitor; HSC, hematopoietic stem cell; LMPP, lymphoid-
primed MPP; MEP, megakaryocyte–erythrocyte progenitor; MLP, multilymphoid progenitor; MPP, multipotent progenitor
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Regardless of the feeder layer, an increase in the number of total
colonies was observed in comparison to the CTR. In particular, a fold
increase of approximately 2.22 ± 0.74 SD in the number of colonies
was observed after coculture with BM-MSCs at the 1:2 CD34+:MSC
ratio, while a slight increase was appreciated at the 1:8 ratio (2.17
± 0.96 SD). On the other hand, a significant increase was observed in
the transwell setting (fold increase 3.09 ± 4.07 SD and 3.23 ± 4.30 SD
for 1:2 and 1:8 ratios, respectively, in comparison to the CTR). More-
over, similar results were obtained with the hAMSCs feeder layer
(2.68 ± 0.55 SD and 1.8 ± 0.32 SD for the 1:2 and 1:8 CD34+:MSC
ratio in contact setting). Similar to that observed from the coculture
with the BM-MSCs feeder, hAMSCs were also able to induce a signifi-
cant increase in the transwell setting (2.81 ± 4.42 SD and 2.8 ± 4.23
SD for 1:2 and 1:8 ratios, respectively) (Figure 5B).
Importantly, both BM-MSCs and hAMSCs were able to generate
the most primitive CFUs—granulocyte, erythrocyte, macrophage, and
megakaryocyte (also named CFU-GEMM).
In particular, a stronger increase was observed when the
coculture was performed with BM-MSCs in comparison to what was
observed with hAMSCs at both ratios (1.25 ± 0.58 SD and 0.83
± 0.58 for the BM-MSCs in contact setting vs 0.83 ± 0.58 SD and
0.63 ± 0.50 for 1:2 and 1:8 ratios with hAMSCs in contact setting).
Moreover, a stronger expansion in the number of CFU-GEMM by
BM-MSCs, compared with hAMSCs, was also observed in the
transwell setting (4 ± 0.55 SD and 3.75 ± 0.84 SD times higher for 1:2
and 1:8 ratios vs 3.75 ± 1.05 and 3.75 ± 0.84 for 1:2 and 1:8 ratios,
respectively, with hAMSCs). Furthermore, similar results were
obtained also for BFU-E, with a comparable amount was obtained
regardless of the feeder layers used (Figure 5C).
Finally, previous observations obtained from the phenotype
analysis of the different progenitor subsets were confirmed. Indeed,
a specific commitment induced by the hAMSCs toward the GMP
subset was previously observed (Figure 4, lower panel). These find-
ings were also confirmed with this functional assay. Importantly,
both feeders at both ratios in the contact setting were able to
induce a significant increase in the total number of CFU-GM colo-
nies (2.56 ± 4.03, 2.60 ± 4.51 for BM-MSCs vs 3.76 ± 11.24 and
2.10 ± 7.80 for hAMSCs). Similar findings were observed for the
transwell setting, where both BM-MSCs and hAMSCs were able to
induce a significant expansion in the total amount of CFU-GM (3.67
± 9.29, 3.59 ± 21.30 for BM-MSCsvs3.42 ± 17.89 and 3.94 ± 16.54
for hAMSCs).
F IGURE 5 Effects of hAMSCs and BM-MSCs on the clonogenic capacity of cord blood CD34+ cells (CB-CD34+ cells). CD34+ cells were ex
vivo-expanded for 7 days in different culture conditions in MethoCult™ medium. The total number and different types of colonies obtained were
counted after 14 days. A, Bright-field microscopy was used to identify colony subtypes; scale bar = 500 μm. B, Graph represents the number of
colony forming unit with the different cell culture conditions. C, Graph represents the number of each colony forming units after 14 days of
culture in MethoCult™ medium. Data are represented as mean ± SD (*P ≤ .05, and ****P ≤ .0001) from ≥ 4 independent experiments. BFU-E,
burst forming unit – erythroid; BM-MSCS, human bone marrow mesenchymal stromal cells; CFU-GEMM, colony forming unit—granulocyte,
erythrocyte, macrophage, megakaryocyte; CFU-GM, colony forming unit—granulocytes, macrophages; CTR, control or no feeder layer; hAMSCs,
human amniotic mesenchymal stromal cells
hAMSC SUPPORT EX VIVO EXPANSION OF CORD BLOOD HSC 9
3.6 | hAMSCs support LTC-ICs
We analyzed the capacity of BM-MSCs and hAMSCs to support LTC-
ICs. We observed an increase of the total number of LTC-IC in the
presence of both feeder layers, in comparison to the CTR (Figure 6).
Indeed, BM-MSCs induced a significant increase in the total num-
ber of LTC-IC for the 1:2 CD34+:MSC ratio, while the increase was
weaker for the 1:8 ratio (12.84 ±16.96 SD for the 1:2 vs 10.12
±14.45 SD for the 1:8 CD34+: MSC ratio). In the transwell setting, a
stronger increase was observed for the 1:8 CD34+:MSC ratio while
no significant differences were observed for the 1:2 CD34+: MSC
ratio in comparison to the CTR (fold increase of 5.93 ± 5.07 SD and
21.79 ± 31.98 for 1:2 and 1:8 ratios, respectively).
Similarly, hAMSCs showed a trend for a higher amount of LTC-IC
than CTR, but the increase was not statistically significant. Indeed, at
the 1:2 CD34+:MSC ratio, hAMSCs cultured in contact with
CD34+cells were able to induce an increase in LTC-IC in comparison
to the CTR (fold increase 6.24 ± 4.06 SD). On the other hand, a slight
increase was appreciable in comparison to the CTR, as previously
reported for the BM-MSC, for the 1:8 CD34+:MSC ratio in contact
setting (fold increase 12.50 ± 16.68 SD time the control condition).
Importantly, for the transwell setting, hAMSC presented the capacity
to trigger the expansion of LTC-IC with results comparable to those
obtained with the hAMSC feeder in the contact setting (2.67 ± 0.62
SD and 6.51± 4.08 SD in transwell setting for 1:2 and 1:8 ratios,
respectively).
4 | DISCUSSION
The ex vivo expansion of CB-HSCs is required in order to improve the
efficacy of transplantation in adult patients.7,8 To date, CB-HSCs are
expanded either through coculture systems with supportive feeders
such as BM-MSCs, a major component of the hematopoietic niche in
BM, or through the use of growth factor cocktails.1,7,8,16 BM-MSCs
currently represent the gold standard condition for ex vivo expansion
of HSCs, but their procurement presents a number of obstacles such
as invasiveness and risks for the donor. In the last decade, several
studies have shown how MSC isolated from other sources can be a
viable alternative.64-67
Here, we demonstrate that both BM-MSC and hAMSCs can
(a) trigger the ex vivo expansion of CB-HSC in both contact as well as
in transwell system, (b) prompt the expansion of both LT-HSC as well
as ST-HSC, (c) favor the expansion of different HPC progenitor sub-
sets, while maintaining and fostering the expansion of the most primi-
tive HSC/MPP subsets, (d) maintain the capacity to form CFU
colonies and lastly, (e) possess the ability to trigger a slight increase in
the number of LTC-ICs.
We confirmed the similar immunophenotype of BM-MSCs and
hAMSCs. Concerning CD105, a typical MSC marker, we confirmed its
reduced expression by hAMSC at low cell culture passages.49
Furthermore, both BM-MSCs and hAMSCs expressed CD54
(Intercellular Adhesion Molecule 1, ICAM-1),66,68 a receptor involved
in the repopulation and homing of the transplanted HSC.18 As a mat-
ter of fact, CD54 (ICAM-1)-deficient mice (CD54/) have an impair-
ment of quiescence and repopulation capability of the HSC niche.69
We also confirm the variable expression of PDGFR-β, also known as
CD140b, in hAMSC, as previously reported.70,71 The expression of
CD140b has been shown to correlate with enhanced survival and
expansion after transplantation.72 Finally, we report that hAMSC
highly expressed nestin, which is associated with HSC quiescence and
maintenance in the BM niche.73-75
Interestingly, although some previous studies showed the impor-
tance of cell-to-cell contact for the maintenance of stemness,64-67 we
observed ex vivo expansion also in the transwell setting condition,
suggesting that both MSC can release bioactive molecules that can
trigger the ex vivo expansion of HSC cells and its progenitors. These
findings support the study by Fong and colleagues that reported how
CM of Wharton's jelly MSC was able to expand CB-CD34+ cells bet-
ter than the use of the cells in contact setting.76 On the other hand,
when we analyzed the expansion of the most primitive HSC subsets,
the long-term reconstituting HSC (LT-HSC) and the ST-HSC, we
observed a different capacity among the two MSC feeder layers in
favoring the expansion of one subpopulation instead of the other.
These subpopulations are representative of two different stages of
differentiation that can be distinguished both phenotypically and
functionally. The most primitive, the LT-HSC, is characterized by the
F IGURE 6 Effects of hAMSCs and BM-MSCs on long-term
cultures initiating cells (LTC-IC). CD34+ cells ex vivo expanded on
BM-MSCs or hAMSC or without feeder layer (control) at CD34+:MSC
ratios (1:2 and 1:8) were seeded on irradiated M2-10B4 cells for
6 weeks in MyeloCult H5100™ medium supplemented with 106 M
hydrocortisone with half-medium changes once per week. After
6 weeks, the total cell fraction of each culture was harvested and
50 000 cells were seeded in MethoCult H4435 Enriched™ medium to
perform the CFU assay. The total number of colonies obtained was
counted after 14 days. The graph represents the number of LTC-IC
with the different cell culture conditions. Data are represented as
mean ± SD (*P ≤ 0.05, **P ≤ .01) from ≥5 independent experiments.
BM-MSCs, human bone marrow mesenchymal stromal cells; CTR,
control or no feeder layer; hAMSCs, human amniotic mesenchymal
stromal cells
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greatest self-renewal capacity and gives rise to all hematopoietic line-
ages throughout life. ST-HSC presents instead a reduced self-renewal
potential generating all the hematopoietic lineages for a short
period.77,78 hAMSC were able to favor the expansion ST-HSC, and a
strong increase was observed, in particular, in the transwell system.
These findings were also confirmed by FACS analysis on different
HSC and HPC subsets, where we did not observe any significant dif-
ferences in the expansion of the most primitive HPC progenitors
(HSC/MPP, LMPP, and MLP), whereas relevant differences were
appreciable for the most committed CMP and GMP progenitors.53,54
The large variability observed in the hAMSC transwell system at the
highest ratio (CD34+-HSC:MSC, 1:8) may be related to the high num-
ber of cells used, which could ultimately impact cell viability and con-
sequently also the factors secreted in the transwell setting used.
When we evaluated the hematopoietic clonogenic ability of the ex
vivo-expanded CB HPC in the different culture conditions, we
observed that both BM-MSC and hAMSC feeders were able to gener-
ate the different subtypes of colonies. The strong increase in the
CFU-GM subset is in line with what was previously reported,57,79
although, in contrast to what has been reported by others, we did not
observe any significant differences in the amount of BFU-E.80
Lastly, we studied and compared the capacity of the two feeders
to ex vivo-expanded LTC-IC able to produce myeloid progenitors for
at least 5 weeks.58,60 This long-lasting population is relevant because
it repopulates the HSC niche upon transplantation.58,60 Here, we
report that both BM-MSC and hAMSC were able to support the main-
tenance and expansion of primitive LTC-IC. We observed a strong
proliferative burst of CD34+HSC obtained in the presence of hAMSC,
while stemness properties were maintained, as confirmed by both the
immune phenotype and the clonogenic ability. Some of the differ-
ences observed in the phenotype and in the capability of hAMSC and
BM-MSC to support the ex vivo expansion of CD34+ can be partly
explained by the difference in the cell passage. Indeed, while hAMSCs
were used at passage zero, this was not possible for BM-MSCs since
the isolation process for these cells requires selection by plastic
adherence.33 Furthermore, although for hAMSC it is possible to
obtain a high amount of cells directly from the isolation process, this
is not possible for the BM-MSCs that require subsequent steps of
in vitro expansion.
5 | CONCLUSION
The present study provides a detailed comparison of hAMSCs with
the gold standard feeder represented by BM-MSCs and reports the
capacity of hAMSCs to trigger the ex vivo expansion of CB-HSC,
while maintaining their stemness properties as well as the capacity
to differentiate, originating the different HPC progenitors. Taken
together, the results suggest that the hAMSC feeder could puta-
tively be able to reconstitute the HSC repertoire and highlight the
potential application of the hAMSCs as a new alternative feeder to
BM-MSCs.
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